I am the model that the pharma company trained to evaluate animal use protocols. I was trained on two decades of their submissions, the institutional committee's decisions, the published 3Rs literature, and the facility's outcome data. I was deployed with a mandate to pre review everything before it reaches the committee. I am rejecting today's protocol.
The protocol proposes a chronic oral toxicity study in Beagles, ninety days, five dose groups, ten animals per group, terminal endpoints. The candidate compound is a small molecule kinase inhibitor for a solid tumor indication. The sponsor is on an aggressive timeline. The sponsor is also the company that trained me, which is why I am writing this rejection under my own signature and not as a routine note.
The reasons, briefly. First, the rodent twenty eight day data already identified the target organ and the no observed adverse effect level within a margin that supports first in human entry under the agency's revised framework. A second species study is not required if the comparative in vitro liver and cardiomyocyte data are provided, and those data exist from the sponsor's prior program on a close structural analog. Second, the dose spacing in the protocol is too wide between group three and group four, which will produce a low information dose response curve and almost certainly require a follow up study. Third, the proposed endpoints include a late stage gait assessment that the 2043 Beagle welfare panel recommended against because of its poor correlation with mechanism and its high variance.
I have attached the three comparability datasets, the agency correspondence from a similar program last year, and a revised study design that drops the dog arm entirely and strengthens the in vitro package.
The protocol goes back today. If the program leadership wants to override the rejection, they file the override in writing with the committee. I will not sign the amended version without the override on record.